Product Theater hosted by Alexion Pharmaceuticals
This talk will establish an overview of hypophosphatasia and review the clinical trial data of asfotase alfa, evaluating the efficacy and safety.
OBJECTIVES
- Establish an overview of hypophosphatasia (HPP) and the critical impact of low ALP.
- Detailed evaluation of the efficacy and safety of asfotase alfa in HPP patients
- Detailed information on support and dosing
If you are planning to attend, Alexion would appreciate your RSVP to:
Tasha Bergman
tasha.bergman@alexion.com
773-750-8070
This speaker is a paid consultant of Alexion Pharmaceuticals, Inc.
The intended audience for this program is healthcare professionals (HCPs) involved in the diagnosis of hypophosphatasia. The program is sponsored by Alexion Pharmaceuticals, Inc.
ALEXION and the Alexion logo are registered trademarks of Alexion Pharmaceuticals, Inc. © 2023, Alexion Pharmaceuticals, Inc. All rights reserved. 121 Seaport Blvd, Boston, MA 02210. US/STQ-H/0458 V2 12/2023
NOTE: This session is a sponsored presentation, and attendees will not receive ACCME credit.
The information in this session is provided by Alexion Pharmaceuticals, Inc. and is not endorsed by ISCD.